Janus Henderson Group
AQST icon

Janus Henderson Group’s Aquestive Therapeutics AQST Stock Holding History

Janus Henderson Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-226,702
Closed -$1.46M – 2409
2025
Q4 		$1.46M Buy
+226,702
New +$1.41M ﹤0.01% 1486

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group's AQST Position: Q1 2026 in Review

Janus Henderson Group sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 226,702 shares — an estimated $1.46M sold.

Janus Henderson Group first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $1.46M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Janus Henderson Group reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Janus Henderson Group sold 226,702 Aquestive Therapeutics shares in Q1 2026, an estimated $1.46M.
  • Janus Henderson Group first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
  • Janus Henderson Group's Aquestive Therapeutics position peaked at $1.46M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.